Outcome of Influenza Infection Managed With Oseltamivir in Lung Transplant Recipients

Ison, Michael G.; Sharma, Amita; Shepard, Jo Anne O.; Wain, John C.; Ginns, Leo C.

doi:10.1016/j.healun.2007.11.575

Cited by 58 publications

(58 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,9,10 Oseltamivir is recommended for LTx recipients with suspected H1N1 and appears to be effective. 3,11 All patients with suspected H1N1 were treated with oseltamivir, although only 4 presented within the recommended time of 48 hours. We could not determine a clear link between this delay and the requirement for mechanical ventilation.…”

Section: Discussionmentioning

confidence: 99%

Pandemic influenza (H1N1): Impact on lung transplant recipients and candidates

Fox

Raviv

Rozengarten

et al. 2010

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Pandemic influenza (H1N1): Impact on lung transplant recipients and candidates

Fox

Raviv

Rozengarten

et al. 2010

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…Transplant patients may benefit from antiviral therapy even after 48-96 h and are likely to require longer duration of therapy [146]. The treatment also reduces the risk of progression to pneumonia and death [156,157]. Resistance to antiviral agents has been described during the 2009 H1N1 outbreak and is a potential concern, especially in immunocompromised populations because of prolonged viral shedding [157].…”

Section: Florescu Langnas and Sandkovskymentioning

confidence: 99%

Opportunistic viral infections in intestinal transplantation

Florescu

Langnas

Sandkovsky

2013

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Intestinal transplantation (IT) has become a standard treatment for patients with intestinal failure and complications of parenteral nutrition. The pool of intestinal transplant recipients has been slowly growing over the last two decades. Of the 2191 ITs performed between 1 January 1990 and 31 March 2012, 50.5% were children less than 10 years of age. Survival rates at 1, 5 and 10 years have been reported to be 78.5, 58.2 and 47%, respectively. IT restores organ functions, but it is associated with complications, with infections representing the major cause of morbidity and mortality in this population.

show abstract

“…During the winter, influenza has been reported to be responsible for up to 42% of upper and 48% of lower respiratory tract infections in SOT recipients (3)(4)(5); available data suggest that between 1% and 4% of SOT patients are infected annually (6,7). Once infected, transplant recipients are known to develop increased viral loads and prolonged shedding, which increases the potential for disease dissemination.…”

Section: Introductionmentioning

confidence: 99%

Influenza Vaccination in the Organ Transplant Recipient: Review and Summary Recommendations

Kumar

Blumberg

Danziger‐Isakov

et al. 2011

American Journal of Transplantation

154

164

View full text Add to dashboard Cite

Influenza virus causes a spectrum of illness in transplant recipients with a high rate of lower respiratory disease. Seasonal influenza vaccination is an important public health measure recommended for transplant recipients and their close contacts. Vaccine has been shown to be safe and generally well tolerated in both adult and pediatric transplant recipients. However, responses to vaccine are variable and are dependent on various factors including time from transplantation and specific immunosuppressive medication. Seasonal influenza vaccine has demonstrated safety and no conclusive evidence exists for a link between vaccination and allograft dysfunction. Annually updated trivalent inactivated influenza vaccines have been available and routinely used for several decades, although newer influenza vaccination formulations including high-dose vaccine, adjuvanted vaccine, quadrivalent inactivated vaccine and vaccine by intradermal delivery system are now available or will be available in the near future. Safety and immunogenicity data of these new formulations in transplant recipients requires investigation. In this document, we review the current state of knowledge on influenza vaccines in transplant recipients and make recommendations on the use of vaccine in both adult and pediatric organ transplant recipients.

show abstract

Outcome of Influenza Infection Managed With Oseltamivir in Lung Transplant Recipients

Cited by 58 publications

References 24 publications

Pandemic influenza (H1N1): Impact on lung transplant recipients and candidates

Pandemic influenza (H1N1): Impact on lung transplant recipients and candidates

Opportunistic viral infections in intestinal transplantation

Influenza Vaccination in the Organ Transplant Recipient: Review and Summary Recommendations

Contact Info

Product

Resources

About